Aradigm
This article was originally published in The Gray Sheet
Executive Summary
Raises $7.8 mil. from a series D venture financing, bringing the company's total financings to $12.4 mil. The funds are allocated for development of the firm's aerosol formulation and pulmonary drug delivery technologies. The Hayward, California-based firm expects its first product, the SmartMist asthma drug delivery system, to be submitted for 510(k) clearance in 1995 ("The Gray Sheet" Nov. 28, p.6)